Denali Therapeutics Changes Fiscal Year End
Ticker: DNLI · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, fiscal-year-change, filing-update
Related Tickers: DNLI
TL;DR
Denali Therapeutics (DNLI) is shifting its fiscal year end to December 31st, effective Nov 12, 2024.
AI Summary
Denali Therapeutics Inc. filed an 8-K on November 18, 2024, reporting a change in its fiscal year end to December 31st. This change was effective as of November 12, 2024. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.
Why It Matters
This change in fiscal year end may impact financial reporting timelines and investor analysis of quarterly and annual performance.
Risk Assessment
Risk Level: low — This filing is administrative and does not involve significant financial or operational changes.
Key Numbers
- 12/31 — New Fiscal Year End (Denali Therapeutics will now close its fiscal year on December 31st.)
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- November 12, 2024 (date) — Effective date of fiscal year change
- November 18, 2024 (date) — Filing date
- December 31 (date) — New fiscal year end
- Delaware (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Principal executive offices
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose is to report an amendment to Denali Therapeutics Inc.'s articles of incorporation or bylaws, specifically concerning a change in its fiscal year end.
When did the change in Denali Therapeutics' fiscal year end become effective?
The change in fiscal year end became effective on November 12, 2024.
What is the new fiscal year end for Denali Therapeutics?
The new fiscal year end for Denali Therapeutics is December 31.
In which state is Denali Therapeutics incorporated?
Denali Therapeutics Inc. is incorporated in Delaware.
What is the address of Denali Therapeutics' principal executive offices?
The principal executive offices of Denali Therapeutics are located at 161 Oyster Point Blvd., South San Francisco, California 94080.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 13.6 · Accepted 2024-11-18 16:02:29
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share DNLI NASDAQ Global Select Mar
Filing Documents
- dnli-20241112.htm (8-K) — 34KB
- amendedandrestatedbylawsof.htm (EX-3.1) — 249KB
- image.jpg (GRAPHIC) — 0KB
- 0001714899-24-000233.txt ( ) — 447KB
- dnli-20241112.xsd (EX-101.SCH) — 2KB
- dnli-20241112_lab.xml (EX-101.LAB) — 22KB
- dnli-20241112_pre.xml (EX-101.PRE) — 13KB
- dnli-20241112_htm.xml (XML) — 3KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 12, 2024, the Board of Directors (the " Board ") of Denali Therapeutics Inc. (the " Company "), acting upon the recommendation of the Board's Corporate Governance and Nominating Committee, approved and adopted amended and restated bylaws (as so amended and restated, the " Amended and Restated Bylaws "), which became effective upon such approval and adoption. Such amendments were adopted in connection with a periodic review of the Company's bylaws, to conform with Securities and Exchange Commission rules regarding universal proxy cards, and to enhance corporate governance in light of recent developments in Delaware law. The Amended and Restated Bylaws, among other things: update and revise the advance notice procedures for the nomination of directors and the proposal of other business at stockholder meetings, including (without limitation) by adding a requirement that a stockholder seeking to nominate director(s) at a meeting of stockholders provide to the Company reasonable evidence that it has complied with the requirements of Rule 14a-19 of the Securities Exchange Act of 1934, as amended, no later than five business days before the meeting, and by requiring additional background information and disclosures regarding proposing stockholders, proposed nominees and business, and other persons related to a stockholder's solicitation of proxies; revise certain additional procedures related to stockholder meetings to conform to the current provisions of the Delaware General Corporation Law (the " DGCL "), including but not limited to provisions relating to delivery of notices of stockholder meetings, quorum, communications regarding adjourned stockholder meetings, conduct of business at meetings, and the preparation of the stockholder list in connection with stockholder meetings; update various provisions regarding directors, Board committees, and officers, including bu
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Bylaws of Denali Therapeutics Inc., effective November 12, 2024 . 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI THERAPEUTICS INC. Date: November 18, 2024 By: /s/ Alexander O. Schuth Alexander O. Schuth, M.D. Chief Operating and Financial Officer